A Review: Ependymomas Disease

  • S. M. Shinde VJSM’S Vishal Institute of Pharmaceutical Education and Research Ale, Junnar, Pune 411 412 Maharashtra, India.
  • U. R. Kumbhar VJSM’S Vishal Institute of Pharmaceutical Education and Research Ale, Junnar, Pune 411 412 Maharashtra, India.
  • D. B. Deshmukh VJSM’S Vishal Institute of Pharmaceutical Education and Research Ale, Junnar, Pune 411 412 Maharashtra, India.
  • D. D. Gaikwad VJSM’S Vishal Institute of Pharmaceutical Education and Research Ale, Junnar, Pune 411 412 Maharashtra, India.
  • N. D. Grampurohit VJSM’S Vishal Institute of Pharmaceutical Education and Research Ale, Junnar, Pune 411 412 Maharashtra, India.
Keywords: morbidity, mortality, modalities, chemo resistance.

Abstract

The ependymomas are relatively not a common tumor. Ependymomas are tumors of the brain and spinal cord that arise from ependymal cells lining the central fluid spaces (ventricles) of the brain and the central canal of the spinal cord. However, most clinicians agree that the radical removal of the is the most important prognostic factor. Tumor removal was not sufficient before the era of magnetic resonance imaging (MRI) and resulted in a considerable operative morbidity and mortality. As the micro neurosurgical techniques and microsurgical anatomy become popular and the MRI provide more detailed anatomical information preoperatively, radical removal of this complex and complicated tumor can be more feasible. In childhood ependymoma, the treatment related morbidity and motility can be the special issues, which can modify the policy of management safe tumor removal and minimal adjuvant treatment, which are extremely important Prognostic factors: although many clinicians believe that the ependymomas are inheritably chemo resistant, the new targets for the treatment are under investigation or clinically tried. Also, the genetic alterations of ependymoma are developing and might be a promising target. The surgical techniques and assistant modalities for tumor removal are still advancing. so, the outcome of ependymoma is still improving. Unfortunately newer treatment modalities, such as new chemotherapeutic agent and gene modification agent are still not promising, the history of ependymoma management is still in progress.
Published
2013-06-25